Cargando…

Clinical Study on the Efficacy of Bevacizumab in Combination with Pembrolizumab on Cellular Immune Function in the Treatment of Driver Gene-Negative Stage IV Lung Adenocarcinoma

PURPOSE: To explore the efficacy of bevacizumab in combination with PD-1 immune drug pembrolizumab on cellular immune function in the treatment of driver gene-negative stage IV lung adenocarcinoma and its short-term survival effect. METHODS: From February 2020 to December 2021, 85 patients with driv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Jun, Gu, Juanjuan, Jiang, Lili, Zhao, Dongxia, Shao, Lili, Chen, Xi, Liu, Jianhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652087/ https://www.ncbi.nlm.nih.gov/pubmed/36385958 http://dx.doi.org/10.1155/2022/7298192

Ejemplares similares

Treatment of gastric hepatoid adenocarcinoma with pembrolizumab and bevacizumab combination chemotherapy: A case report
por: Liu, Mei, et al.
Publicado: (2022)

Campylobacteremia in stage IV gliosarcoma with bevacizumab treatment
por: Liu, Ping
Publicado: (2012)

Abscopal Effect in a Stage IV Melanoma Patient who Progressed on Pembrolizumab
por: Tsui, James M, et al.
Publicado: (2018)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma
por: Oldan, Jorge D., et al.
Publicado: (2023)

Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible
por: Kedia, Shiksha, et al.
Publicado: (2015)

From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report
por: Vernmark, Karolina, et al.
Publicado: (2015)

Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report
por: Webb, Mason J, et al.
Publicado: (2023)

Bevacizumab Combined With Oxaliplatin/Capecitabine in Patient With Refractory and Recurrent Mucinous Adenocarcinoma of the Appendix: A Case Report
por: Liu, Wenzhi, et al.
Publicado: (2019)

Pan-Driver-Negatives versus Epidermal Growth Factor Receptor Mutants for C-Stage IA Lung Adenocarcinoma with Ground-Glass Opacity
por: Li, Ming, et al.
Publicado: (2022)

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study
por: Pujol, Jean-Louis, et al.
Publicado: (2021)

Real-World Outcomes of Nivolumab, Pembrolizumab, and Atezolizumab Treatment Efficacy in Korean Veterans with Stage IV Non-Small-Cell Lung Cancer
por: Ham, Ahrong, et al.
Publicado: (2023)

Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations
por: Liao, Jiatao, et al.
Publicado: (2021)

Treatment of Stage IV Non–Small Cell Lung Cancer with Pembrolizumab in Combination with Platinum-Based Doublet Chemotherapy in Vietnam
por: Nguyen, Khanh Toan, et al.
Publicado: (2023)

Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab
por: Bagegni, Nusayba A, et al.
Publicado: (2022)

Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Lung Adenocarcinoma with Paraneoplastic Hyper-Eosinophilia Not Responding To Pembrolizumab
por: Wehbe, Hisham, et al.
Publicado: (2021)

Combination of Palliative Thoracic Radiotherapy With Bevacizumab for Stage IV Nonsquamous NSCLC: Is There Any Impact of Time Interval on Survival?
por: Xiu, Weigang, et al.
Publicado: (2022)

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study
por: Lee, Suey-Haur, et al.
Publicado: (2022)

Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report
por: Liu, Yanxin, et al.
Publicado: (2023)

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
por: Huang, Min, et al.
Publicado: (2023)

Stage IV jejunal adenocarcinoma: a multimodal therapeutic success story
por: Seomangal, Karishma, et al.
Publicado: (2019)

Dysgonomonas capnocytophagoides Bacteremia in a Patient With Stage IV Colon Adenocarcinoma
por: Schall, Sarah E, et al.
Publicado: (2021)

A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma
por: Wu, Lili, et al.
Publicado: (2021)

Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery
por: Tilgase, Andra, et al.
Publicado: (2018)

The outcome of primary tumor resection in the unresectable stage IV colorectal cancer patients who received the bevacizumab-containing chemotherapy
por: Yeom, Seung-Seop, et al.
Publicado: (2020)

Development of an Oncogenic Driver Alteration Associated Immune-Related Prognostic Model for Stage I-II Lung Adenocarcinoma
por: Xu, Jian-Zhao, et al.
Publicado: (2021)

Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases
por: Yang, Gang, et al.
Publicado: (2022)

Complete remission of an early-stage laryngeal cancer under combined pembrolizumab and chemotherapy treatment of a synchronous lung adenocarcinoma
por: Linxweiler, Maximilian, et al.
Publicado: (2022)

Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population
por: Pankaj, Goyal, et al.
Publicado: (2016)

Uncovering Driver DNA Methylation Events in Nonsmoking Early Stage Lung Adenocarcinoma
por: Zhang, Xindong, et al.
Publicado: (2016)

Pathologic subtype-defined prognosis is dependent on both tumor stage and status of oncogenic driver mutations in lung adenocarcinoma
por: Dong, Yu, et al.
Publicado: (2017)

Bevacizumab-Induced Reversible Thrombocytopenia in a Patient with Adenocarcinoma of Colon: Rare Adverse Effect of Bevacizumab
por: Kumar, Jeevan, et al.
Publicado: (2012)

Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma
por: Puppa, G, et al.
Publicado: (2007)

Obstructing Stage IV Adenocarcinoma of the Transverse Colon in a Young Patient With Vitiligo
por: Mueller, Ellie, et al.
Publicado: (2023)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
por: Jafari, Abdosaleh, et al.
Publicado: (2023)

Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma
por: Kobak, Senol
Publicado: (2019)

Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
por: Kurokawa, Kana, et al.
Publicado: (2019)

Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma
por: Akagi, Yu, et al.
Publicado: (2020)

Retrobulbar Optic Neuritis Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
por: Kawakado, Keita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gst14emta48oef8f4o66and4g2